Silpa Avula, MD
Cardiovascular Disease (Cardiology) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 35
- 9 carriers
- Offices
- 2
Offices
2 locations · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
35 plans · 9 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Avula’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
35 of 35 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A76357 · Current
Licensed to practise in California · since 2001 · expires 2027-08-31 · Kakatiya University, Kakatiya Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$246,842
Medicare paid this office $246,842 for 269 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 56 | $93,465 | $1,669 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 56 | $48,467 | $433 |
| Return visit (30+ min) | 178 | $36,937 | $120 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 113 | $23,854 | $211 |
| Short return visit (20+ min) | 92 | $8,837 | $89 |
See all 18 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 56 | $93,465 | $1,669 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 56 | $48,467 | $433 |
| Return visit (30+ min) | 178 | $36,937 | $120 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 113 | $23,854 | $211 |
| Short return visit (20+ min) | 92 | $8,837 | $89 |
| New patient visit (45+ min) | 50 | $8,069 | $161 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 14 | $6,961 | $497 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 71 | $5,351 | $75 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 44 | $2,874 | $65 |
| Injection of drug or substance into vein | 69 | $2,854 | $41 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 14 | $2,121 | $76 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,340 | $71 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 73 | $1,058 | $14 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 44 | $715 | None |
| Injection, regadenoson, 0.1 mg | 13 | $321 | None |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 13 | $314 | $24 |
| Heart rhythm recording of continous external ekg over 8-15 days | 12 | $168 | $14 |
| Infusion, normal saline solution, 250 cc | 70 | $36 | None |
Who their Medicare patients are
269 Original Medicare patients in 2024. Average age 77 · Under 65 7% · 85 and older 22% · Women 58% · Also on Medicaid 52% · Health risk score 1.71. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Diabetes 62% · Coronary heart disease 39% · Heart failure 28% · Chronic kidney disease 26% · Atrial fibrillation 24% · Depression 19% · COPD 15% · Stroke 15% · Dementia 13% · Cancer 11%.
The office billed $541,991, Medicare allowed $312,413 and paid $246,842; for 2,939 services of 30 kinds; $1,072 of it was for drugs given in the office and $245,770 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 269 | 2,939 | 77 | 1.71 | $541,991 | $246,842 |
| 2023 | 399 | 4,441 | 77 | 1.79 | $635,618 | $277,127 |
| 2022 | 435 | 6,510 | 77 | 2.00 | $799,530 | $352,786 |
| 2021 | 397 | 6,969 | 77 | 1.89 | $843,367 | $382,230 |
| 2020 | 425 | 4,445 | 76 | 2.09 | $511,881 | $209,971 |
| 2019 | 537 | 10,479 | 77 | 2.19 | $1,075,503 | $460,850 |
| 2018 | 547 | 11,838 | 76 | 2.36 | $1,171,911 | $477,189 |
| 2017 | 627 | 13,164 | 77 | 2.29 | $1,468,948 | $557,618 |
| 2016 | 465 | 9,202 | 77 | 2.11 | $1,061,509 | $388,155 |
| 2015 | 499 | 7,678 | 76 | 2.18 | $976,650 | $349,138 |
| 2014 | 560 | 8,707 | 76 | 1.93 | $904,405 | $411,218 |
| 2013 | 524 | 2,822 | 76 | 2.10 | $564,078 | $340,354 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 18 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 62 | $99,666 | $1,608 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 61 | $50,814 | $417 |
| Return visit (30+ min) | 203 | $44,222 | $115 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 114 | $23,360 | $200 |
| Short return visit (20+ min) | 111 | $10,492 | $77 |
| New patient visit (45+ min) | 62 | $9,444 | $152 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 118 | $7,486 | $63 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 14 | $6,776 | $484 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 76 | $5,372 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,613 | $109 |
| Injection of drug or substance into vein | 76 | $3,069 | $40 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 15 | $2,134 | $71 |
| Programming of dual lead pacemaker system | 11 | $1,088 | $78 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 65 | $1,039 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 60 | $800 | $13 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 19 | $430 | $23 |
| Heart rhythm recording of continous external ekg over 8-15 days | 20 | $256 | $13 |
| Infusion, normal saline solution, 250 cc | 76 | $234 | None |
2022: 20 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 89 | $142,137 | $1,597 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 89 | $74,096 | $416 |
| Return visit (30+ min) | 205 | $40,678 | $111 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 95 | $19,927 | $203 |
| Short return visit (20+ min) | 176 | $16,955 | $78 |
| New patient visit (45+ min) | 78 | $11,450 | $147 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 121 | $8,144 | $65 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 101 | $7,237 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $5,973 | $92 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $5,277 | $480 |
| Injection of drug or substance into vein | 100 | $4,245 | $42 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,911 | $178 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 12 | $2,126 | $89 |
| Programming of dual lead pacemaker system | 17 | $1,790 | $78 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 98 | $1,566 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 94 | $1,181 | $12 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 11 | $676 | $61 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 22 | $522 | $24 |
| Infusion, normal saline solution, 250 cc | 100 | $384 | None |
| Heart rhythm recording of continous external ekg over 8-15 days | 22 | $331 | $15 |
2021: 22 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 89 | $146,239 | $1,625 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 91 | $76,854 | $418 |
| Return visit (30+ min) | 182 | $39,344 | $120 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 126 | $27,203 | $216 |
| Short return visit (20+ min) | 143 | $15,373 | $86 |
| New patient visit (45+ min) | 52 | $8,263 | $159 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $7,861 | $94 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 15 | $7,691 | $513 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 107 | $7,670 | $71 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,798 | $174 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $6,745 | $65 |
| Telephone medical discussion with physician, 21-30 minutes | 51 | $5,161 | $89 |
| Injection of drug or substance into vein | 104 | $4,668 | $44 |
| Telephone medical discussion with physician, 11-20 minutes | 51 | $3,740 | $67 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 15 | $2,673 | $89 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 103 | $2,054 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 97 | $1,443 | $14 |
| Programming of dual lead pacemaker system | 12 | $1,298 | $72 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 13 | $1,005 | $77 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 19 | $480 | $25 |
| Infusion, normal saline solution, 250 cc | 105 | $396 | None |
| Heart rhythm recording of continous external ekg over 8-15 days | 20 | $323 | $16 |
2020: 22 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 27 | $44,623 | $1,653 |
| Return visit (30+ min) | 201 | $29,746 | $97 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 27 | $22,555 | $418 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 90 | $19,593 | $211 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 36 | $18,487 | $514 |
| Telephone medical discussion with physician, 21-30 minutes | 92 | $11,207 | $101 |
| Telephone medical discussion with physician, 11-20 minutes | 117 | $10,275 | $69 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 122 | $8,616 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $6,987 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,566 | $188 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 36 | $6,562 | $90 |
| Short return visit (20+ min) | 76 | $6,058 | $67 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 63 | $4,296 | $67 |
| New patient visit (45+ min) | 24 | $3,644 | $152 |
| Injection of drug or substance into vein | 63 | $2,657 | $42 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 22 | $1,544 | $67 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 63 | $1,303 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 59 | $1,031 | $17 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $717 | $48 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 13 | $324 | $25 |
| External ekg recording for more than 48 hours up to 21 days | 11 | $314 | $29 |
| Infusion, normal saline solution, 250 cc | 63 | $132 | None |
2019: 21 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 106 | $165,354 | $1,560 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 108 | $89,641 | $415 |
| Return visit (30+ min) | 288 | $72,501 | $98 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 169 | $34,398 | $201 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $15,556 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 58 | $11,032 | $184 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 161 | $10,858 | $67 |
| Short return visit (20+ min) | 113 | $8,924 | $68 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 119 | $8,293 | $70 |
| New patient visit (45+ min) | 51 | $7,771 | $152 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 12 | $6,155 | $513 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 67 | $5,368 | $80 |
| Injection of drug or substance into vein | 119 | $4,859 | $41 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 117 | $4,202 | None |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 12 | $2,125 | $89 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 98 | $1,690 | $16 |
| Long return visit (40+ min) | 11 | $1,527 | $139 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 16 | $1,066 | $43 |
| Infusion, normal saline solution, 250 cc | 120 | $385 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 16 | $327 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 16 | $220 | $14 |
2018: 23 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 120 | $187,371 | $1,536 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 121 | $86,565 | $352 |
| Return visit (30+ min) | 293 | $70,262 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 159 | $32,339 | $198 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $14,530 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $12,453 | $175 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 179 | $11,631 | $64 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 138 | $9,327 | $67 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 16 | $7,765 | $485 |
| New patient visit (45+ min) | 47 | $6,953 | $148 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 81 | $6,592 | $79 |
| Injection of drug or substance into vein | 137 | $6,491 | $47 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 134 | $4,987 | None |
| Short return visit (20+ min) | 53 | $3,904 | $65 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 13 | $3,242 | $249 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 16 | $2,704 | $84 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 101 | $1,640 | $15 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 22 | $1,129 | $33 |
| Infusion, normal saline solution, 250 cc | 137 | $441 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 20 | $390 | $19 |
| External ekg recording for more than 48 hours up to 21 days | 11 | $303 | $28 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 11 | $262 | $24 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 20 | $261 | $13 |
2017: 25 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 138 | $201,677 | $1,461 |
| Return visit (30+ min) | 338 | $82,188 | $100 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 142 | $65,452 | $230 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 215 | $49,434 | $223 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 99 | $24,360 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 120 | $24,094 | $181 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 31 | $15,621 | $504 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 170 | $12,705 | $73 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 190 | $11,646 | $57 |
| New patient visit (45+ min) | 76 | $11,177 | $147 |
| Injection of drug or substance into vein | 171 | $10,118 | $59 |
| Short return visit (20+ min) | 103 | $8,215 | $66 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 30 | $7,597 | $253 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 94 | $6,956 | $74 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 31 | $5,400 | $87 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 147 | $4,057 | None |
| Ultrasound of both sides of head and neck blood flow | 18 | $3,311 | $184 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 148 | $2,430 | $16 |
| Programming of dual lead pacemaker system | 15 | $1,286 | $54 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,184 | $99 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 23 | $1,012 | $33 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 42 | $863 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 40 | $552 | $13 |
| Infusion, normal saline solution, 250 cc | 172 | $411 | None |
| Insertion of needle into vein for collection of blood sample | 12 | $68 | $3 |
2016: 25 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 67 | $97,439 | $1,433 |
| Return visit (30+ min) | 277 | $76,229 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 164 | $36,976 | $216 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 74 | $35,908 | $485 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 67 | $30,805 | $227 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 89 | $16,506 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 82 | $15,335 | $91 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 75 | $13,067 | $87 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 140 | $9,715 | $68 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 98 | $8,059 | $77 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 31 | $8,014 | $259 |
| New patient visit (45+ min) | 46 | $6,853 | $149 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 111 | $6,233 | $56 |
| Injection of drug or substance into vein | 98 | $5,641 | $57 |
| Ultrasound of both sides of head and neck blood flow | 21 | $3,968 | $189 |
| Short return visit (20+ min) | 51 | $3,699 | $67 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 101 | $3,470 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 110 | $2,021 | $16 |
| Programming of dual lead pacemaker system | 15 | $977 | $49 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 15 | $798 | $33 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $609 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 22 | $432 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 22 | $282 | $13 |
| Infusion, normal saline solution, 250 cc | 141 | $224 | None |
| Insertion of needle into vein for collection of blood sample | 16 | $200 | $3 |
2015: 23 services
| Return visit (30+ min) | 274 | $71,715 | $98 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 115 | $57,974 | $504 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 30 | $43,104 | $1,437 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 169 | $38,170 | $222 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 115 | $19,186 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 96 | $17,224 | $92 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 32 | $14,707 | $230 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $14,115 | $181 |
| New patient visit (45+ min) | 90 | $13,632 | $151 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 146 | $9,878 | $67 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 33 | $8,746 | $257 |
| Injection of drug or substance into vein | 146 | $8,596 | $58 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 86 | $7,259 | $80 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 119 | $6,761 | $57 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 98 | $3,289 | None |
| Ultrasound of both sides of head and neck blood flow | 13 | $2,598 | $200 |
| Short return visit (20+ min) | 38 | $2,546 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 129 | $2,247 | $16 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 25 | $1,382 | $35 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 16 | $321 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 16 | $209 | $13 |
| Insertion of needle into vein for collection of blood sample | 18 | $203 | $3 |
| Infusion, normal saline solution, 250 cc | 145 | $115 | None |
2014: 19 services
| Return visit (30+ min) | 307 | $92,094 | $95 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 173 | $88,059 | $498 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 231 | $54,000 | $223 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 142 | $32,160 | $92 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 166 | $29,077 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 114 | $21,880 | $179 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 51 | $14,206 | $268 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 128 | $11,918 | None |
| New patient visit (45+ min) | 81 | $11,858 | $146 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 126 | $11,469 | $83 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 173 | $11,319 | $63 |
| Injection of drug or substance into vein | 139 | $8,112 | $57 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 142 | $8,039 | $56 |
| Short return visit (20+ min) | 32 | $2,316 | $68 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 22 | $1,144 | $34 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 67 | $1,069 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 34 | $675 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 34 | $443 | $13 |
| Infusion, normal saline solution, 250 cc | 143 | $38 | None |
2013: 18 services
| Return visit (30+ min) | 279 | $91,035 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 141 | $72,695 | $516 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 143 | $37,288 | $132 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 151 | $28,935 | $187 |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 139 | $24,293 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 118 | $23,024 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 87 | $17,169 | $172 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 35 | $9,747 | $263 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 141 | $9,376 | $66 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 159 | $8,875 | $54 |
| New patient visit (45+ min) | 49 | $7,293 | $149 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,678 | $88 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 24 | $1,568 | $35 |
| Short return visit (20+ min) | 23 | $1,549 | $67 |
| Ultrasound of heart with probe in esophagus, with report | 16 | $1,537 | $90 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 77 | $1,445 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 26 | $500 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 26 | $331 | $13 |
Medicaid work
$7,538 in 2024
Medicaid paid $7,538 for 596 billed services this clinician did in 2024, up to 59 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 284 | $4,271 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 183 | $2,801 |
| Short return visit (20+ min) | 89 | $281 |
| CARDIOVASCULAR STRESS TEST | 12 | $89 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug | 12 | $48 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 16 | $47 |
| 2024 | 596 | 6 | 59 | $7,538 |
| 2023 | 1,470 | 10 | 54 | $23,648 |
| 2022 | 1,065 | 11 | 57 | $16,450 |
| 2021 | 915 | 11 | 43 | $4,592 |
| 2020 | 380 | 5 | 46 | $2,106 |
| 2019 | 420 | 4 | 28 | $1,479 |
| 2018 | 244 | 3 | 29 | $1,736 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 320 | $7,747 |
| Return visit (30+ min) | 406 | $4,604 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 40 | $3,869 |
| New patient visit (45+ min) | 160 | $2,845 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 40 | $1,430 |
| Short return visit (20+ min) | 178 | $1,215 |
| CARDIOVASCULAR STRESS TEST | 111 | $796 |
| Injection, regadenoson, 0.1 mg | 12 | $769 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 173 | $368 |
| Infusion, normal saline solution, 250 cc | 30 | $5 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 239 | $7,049 |
| New patient visit (45+ min) | 103 | $2,242 |
| Return visit (30+ min) | 259 | $1,864 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 14 | $1,407 |
| Short return visit (20+ min) | 185 | $1,301 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 14 | $1,267 |
| CARDIOVASCULAR STRESS TEST | 33 | $519 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 146 | $457 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug | 27 | $244 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 29 | $90 |
| Infusion, normal saline solution, 250 cc | 16 | $11 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 179 | $3,136 |
| Return visit (30+ min) | 189 | $485 |
| CARDIOVASCULAR STRESS TEST | 77 | $379 |
| Short return visit (20+ min) | 164 | $220 |
| New patient visit (45+ min) | 70 | $179 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 130 | $117 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug | 47 | $53 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 19 | $19 |
| Infusion, normal saline solution, 250 cc | 16 | $3 |
| Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 12 | $0 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 12 | $0 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 145 | $1,887 |
| Return visit (30+ min) | 121 | $105 |
| Short return visit (20+ min) | 89 | $62 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 12 | $42 |
| CARDIOVASCULAR STRESS TEST | 13 | $11 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 128 | $1,184 |
| Return visit (30+ min) | 113 | $181 |
| Short return visit (20+ min) | 164 | $82 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 15 | $32 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 100 | $1,469 |
| Return visit (30+ min) | 132 | $230 |
| CARDIOVASCULAR STRESS TEST | 12 | $37 |
Drugs they prescribed that Part D paid
$420,937
Pharmacies billed $420,937 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,680) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
1,357 generic and 323 brand-name prescriptions · $420,937 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 114 | $168,439 | $1,478 |
| Xarelto | 56 | $82,483 | $1,473 |
| Entresto | 48 | $62,666 | $1,306 |
| Jardiance | 27 | $36,303 | $1,345 |
| Farxiga | 17 | $23,926 | $1,407 |
See all 30 drugs
| Eliquis | 114 | $168,439 | $1,478 |
| Xarelto | 56 | $82,483 | $1,473 |
| Entresto | 48 | $62,666 | $1,306 |
| Jardiance | 27 | $36,303 | $1,345 |
| Farxiga | 17 | $23,926 | $1,407 |
| Brilinta | 14 | $11,840 | $846 |
| Repatha | 12 | $6,381 | $532 |
| Ranolazine Er | 18 | $2,887 | $160 |
| Metoprolol | 141 | $2,451 | $17 |
| Atorvastatin | 105 | $1,423 | $14 |
| Losartan | 110 | $1,243 | $11 |
| Amiodarone | 17 | $1,229 | $72 |
| Hydralazine | 92 | $1,037 | $11 |
| Clopidogrel | 67 | $972 | $15 |
| Ezetimibe | 21 | $905 | $43 |
| Losartan-Hydrochlorothiazide | 47 | $854 | $18 |
| Amlodipine Besylate | 155 | $833 | $5 |
| Carvedilol | 55 | $636 | $12 |
| Furosemide | 83 | $588 | $7 |
| Potassium Chloride | 36 | $532 | $15 |
| Metoprolol | 86 | $508 | $6 |
| Isosorbide Mononitrate Er | 50 | $436 | $9 |
| Lisinopril | 37 | $395 | $11 |
| Nitroglycerin | 43 | $300 | $7 |
| Digoxin | 14 | $300 | $21 |
| Spironolactone | 19 | $213 | $11 |
| Atenolol | 25 | $179 | $7 |
| Rosuvastatin | 14 | $165 | $12 |
| Hydrochlorothiazide | 22 | $104 | $5 |
| Simvastatin | 14 | $91 | $6 |
Year by year
| 2024 | 1,680 | 310 | 0% (0) | 19% | $420,937 |
| 2023 | 1,809 | 288 | 0% (0) | 16% | $378,492 |
| 2022 | 1,878 | 295 | 0% (0) | 16% | $303,304 |
| 2021 | 2,108 | 284 | 0% (0) | 18% | $299,831 |
| 2020 | 2,401 | 292 | 0% (0) | 18% | $308,905 |
| 2019 | 2,576 | 318 | 0% (0) | 19% | $287,205 |
| 2018 | 2,227 | 282 | 0% (0) | 18% | $221,781 |
| 2017 | 2,378 | 281 | 0% (0) | 20% | $204,014 |
| 2016 | 2,371 | 253 | 0% (0) | 22% | $179,858 |
| 2015 | 2,211 | 223 | 0% (0) | 21% | $136,979 |
| 2014 | 2,068 | 196 | 0% (0) | 24% | $125,762 |
| 2013 | 2,113 | 170 | 0% (0) | None | $136,448 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Eliquis | 121 | $181,881 | $1,503 |
| Xarelto | 51 | $62,941 | $1,234 |
| Entresto | 29 | $47,289 | $1,631 |
| Brilinta | 23 | $20,072 | $873 |
| Ranolazine Er | 34 | $6,309 | $186 |
| Metoprolol | 142 | $3,514 | $25 |
| Amlodipine Besylate | 218 | $3,070 | $14 |
| Ezetimibe | 30 | $2,860 | $95 |
| Atorvastatin | 137 | $2,563 | $19 |
| Losartan | 118 | $1,998 | $17 |
| Hydralazine | 78 | $1,907 | $24 |
| Amiodarone | 20 | $1,896 | $95 |
| Clopidogrel | 77 | $1,577 | $20 |
| Losartan-Hydrochlorothiazide | 52 | $1,542 | $30 |
| Metoprolol | 105 | $1,524 | $15 |
| Carvedilol | 64 | $1,049 | $16 |
| Isosorbide Mononitrate Er | 54 | $865 | $16 |
| Lisinopril | 60 | $821 | $14 |
| Digoxin | 21 | $638 | $30 |
| Furosemide | 71 | $540 | $8 |
| Nitroglycerin | 41 | $481 | $12 |
| Potassium Chloride | 16 | $435 | $27 |
| Atenolol | 20 | $230 | $11 |
| Hydrochlorothiazide | 31 | $177 | $6 |
| Simvastatin | 23 | $163 | $7 |
| Rosuvastatin | 15 | $163 | $11 |
2022: 29 drugs
| Eliquis | 131 | $155,949 | $1,190 |
| Xarelto | 32 | $40,284 | $1,259 |
| Brilinta | 35 | $25,894 | $740 |
| Entresto | 29 | $24,279 | $837 |
| Ranolazine Er | 32 | $5,252 | $164 |
| Amiodarone | 25 | $3,385 | $135 |
| Metoprolol | 140 | $2,965 | $21 |
| Ezetimibe | 16 | $2,868 | $179 |
| Losartan-Hydrochlorothiazide | 58 | $2,000 | $34 |
| Clopidogrel | 89 | $1,870 | $21 |
| Atorvastatin | 130 | $1,708 | $13 |
| Amlodipine Besylate | 208 | $1,691 | $8 |
| Losartan | 123 | $1,575 | $13 |
| Hydralazine | 74 | $1,397 | $19 |
| Digoxin | 38 | $1,265 | $33 |
| Metoprolol | 123 | $1,183 | $10 |
| Carvedilol | 59 | $874 | $15 |
| Potassium Chloride | 37 | $837 | $23 |
| Isosorbide Mononitrate Er | 49 | $801 | $16 |
| Lisinopril | 54 | $734 | $14 |
| Nitroglycerin | 55 | $696 | $13 |
| Rosuvastatin | 18 | $599 | $33 |
| Furosemide | 83 | $505 | $6 |
| Simvastatin | 29 | $374 | $13 |
| Warfarin | 15 | $292 | $19 |
| Olmesartan Medoxomil | 11 | $250 | $23 |
| Hydrochlorothiazide | 32 | $212 | $7 |
| Atenolol | 12 | $178 | $15 |
| Pantoprazole | 12 | $65 | $5 |
2021: 31 drugs
| Eliquis | 170 | $166,258 | $978 |
| Xarelto | 38 | $41,874 | $1,102 |
| Entresto | 34 | $24,157 | $710 |
| Brilinta | 24 | $16,127 | $672 |
| Ranolazine Er | 29 | $5,460 | $188 |
| Metoprolol | 155 | $3,589 | $23 |
| Amiodarone | 17 | $2,547 | $150 |
| Atorvastatin | 136 | $2,136 | $16 |
| Amlodipine Besylate | 242 | $1,951 | $8 |
| Ezetimibe | 26 | $1,947 | $75 |
| Losartan | 119 | $1,722 | $14 |
| Potassium Chloride | 44 | $1,484 | $34 |
| Clopidogrel | 99 | $1,398 | $14 |
| Metoprolol | 162 | $1,327 | $8 |
| Losartan-Hydrochlorothiazide | 38 | $1,245 | $33 |
| Digoxin | 34 | $1,232 | $36 |
| Isosorbide Mononitrate Er | 69 | $1,100 | $16 |
| Diltiazem | 19 | $1,046 | $55 |
| Hydralazine | 57 | $891 | $16 |
| Nitroglycerin | 53 | $882 | $17 |
| Carvedilol | 51 | $846 | $17 |
| Furosemide | 110 | $809 | $7 |
| Lisinopril | 61 | $652 | $11 |
| Rosuvastatin | 13 | $566 | $44 |
| Simvastatin | 34 | $522 | $15 |
| Warfarin | 30 | $414 | $14 |
| Pravastatin | 15 | $302 | $20 |
| Klor-Con 10 | 21 | $262 | $12 |
| Atenolol | 20 | $190 | $10 |
| Benazepril | 13 | $189 | $15 |
| Hydrochlorothiazide | 32 | $98 | $3 |
2020: 33 drugs
| Eliquis | 169 | $143,833 | $851 |
| Xarelto | 37 | $44,675 | $1,207 |
| Entresto | 53 | $31,249 | $590 |
| Brilinta | 34 | $26,003 | $765 |
| Ranolazine Er | 36 | $9,028 | $251 |
| Amiodarone | 13 | $3,746 | $288 |
| Metoprolol | 152 | $3,617 | $24 |
| Ezetimibe | 26 | $2,407 | $93 |
| Atorvastatin | 148 | $2,257 | $15 |
| Potassium Chloride | 69 | $2,149 | $31 |
| Hydralazine | 97 | $1,936 | $20 |
| Losartan | 138 | $1,889 | $14 |
| Omega-3 Acid Ethyl Esters | 12 | $1,883 | $157 |
| Amlodipine Besylate | 262 | $1,879 | $7 |
| Losartan-Hydrochlorothiazide | 36 | $1,867 | $52 |
| Isosorbide Mononitrate Er | 79 | $1,583 | $20 |
| Digoxin | 37 | $1,534 | $41 |
| Nitroglycerin | 82 | $1,417 | $17 |
| Metoprolol | 218 | $1,379 | $6 |
| Clopidogrel | 92 | $1,031 | $11 |
| Valsartan-Hydrochlorothiazide | 11 | $1,008 | $92 |
| Metolazone | 15 | $955 | $64 |
| Warfarin | 65 | $891 | $14 |
| Bumetanide | 12 | $801 | $67 |
| Diltiazem | 19 | $796 | $42 |
| Furosemide | 131 | $763 | $6 |
| Carvedilol | 63 | $703 | $11 |
| Lisinopril | 44 | $695 | $16 |
| Simvastatin | 32 | $631 | $20 |
| Pravastatin | 29 | $520 | $18 |
| Atenolol | 16 | $280 | $18 |
| Hydrochlorothiazide | 38 | $201 | $5 |
| Benazepril | 14 | $173 | $12 |
2019: 34 drugs
| Eliquis | 178 | $138,198 | $776 |
| Brilinta | 46 | $34,975 | $760 |
| Xarelto | 39 | $28,370 | $727 |
| Entresto | 45 | $18,090 | $402 |
| Ranolazine Er | 18 | $7,826 | $435 |
| Metoprolol | 132 | $3,941 | $30 |
| Amiodarone | 26 | $2,921 | $112 |
| Ezetimibe | 32 | $2,782 | $87 |
| Atorvastatin | 154 | $2,465 | $16 |
| Potassium Chloride | 78 | $2,435 | $31 |
| Omega-3 Acid Ethyl Esters | 11 | $2,191 | $199 |
| Isosorbide Mononitrate Er | 99 | $1,932 | $20 |
| Amlodipine Besylate | 253 | $1,897 | $7 |
| Metoprolol | 251 | $1,782 | $7 |
| Diltiazem | 34 | $1,527 | $45 |
| Digoxin | 41 | $1,430 | $35 |
| Hydralazine | 72 | $1,393 | $19 |
| Losartan | 132 | $1,322 | $10 |
| Clopidogrel | 91 | $1,168 | $13 |
| Nitroglycerin | 64 | $1,128 | $18 |
| Rosuvastatin | 16 | $1,023 | $64 |
| Furosemide | 174 | $1,004 | $6 |
| Warfarin | 72 | $998 | $14 |
| Bumetanide | 11 | $917 | $83 |
| Losartan-Hydrochlorothiazide | 53 | $815 | $15 |
| Metolazone | 17 | $794 | $47 |
| Carvedilol | 82 | $768 | $9 |
| Lisinopril | 57 | $658 | $12 |
| Simvastatin | 36 | $515 | $14 |
| Pravastatin | 22 | $440 | $20 |
| Atenolol | 20 | $384 | $19 |
| Diltiazem 24hr Er (Cd) | 13 | $334 | $26 |
| Benazepril | 18 | $167 | $9 |
| Hydrochlorothiazide | 41 | $156 | $4 |
2018: 37 drugs
| Eliquis | 119 | $89,865 | $755 |
| Brilinta | 46 | $30,312 | $659 |
| Ranexa | 29 | $21,482 | $741 |
| Xarelto | 38 | $16,119 | $424 |
| Entresto | 15 | $8,467 | $564 |
| Metoprolol | 134 | $4,061 | $30 |
| Amiodarone | 30 | $3,467 | $116 |
| Atorvastatin | 136 | $2,801 | $21 |
| Omega-3 Acid Ethyl Esters | 13 | $2,363 | $182 |
| Potassium Chloride | 81 | $2,232 | $28 |
| Isosorbide Mononitrate Er | 118 | $2,131 | $18 |
| Ezetimibe | 30 | $1,838 | $61 |
| Diltiazem | 38 | $1,585 | $42 |
| Amlodipine Besylate | 179 | $1,535 | $9 |
| Warfarin | 84 | $1,495 | $18 |
| Rosuvastatin | 26 | $1,476 | $57 |
| Bumetanide | 13 | $1,475 | $113 |
| Clopidogrel | 103 | $1,408 | $14 |
| Digoxin | 27 | $1,385 | $51 |
| Metoprolol | 197 | $1,339 | $7 |
| Nitroglycerin | 61 | $1,302 | $21 |
| Losartan | 107 | $1,225 | $11 |
| Hydralazine | 57 | $975 | $17 |
| Furosemide | 124 | $736 | $6 |
| Cartia Xt | 11 | $590 | $54 |
| Simvastatin | 36 | $567 | $16 |
| Carvedilol | 42 | $552 | $13 |
| Lisinopril | 51 | $533 | $10 |
| Pravastatin | 13 | $424 | $33 |
| Atenolol | 28 | $360 | $13 |
| Valsartan | 14 | $316 | $23 |
| Losartan-Hydrochlorothiazide | 30 | $285 | $10 |
| Diltiazem 24hr Er (Cd) | 14 | $233 | $17 |
| Omeprazole | 14 | $208 | $15 |
| Hydrochlorothiazide | 25 | $134 | $5 |
| Benazepril | 11 | $101 | $9 |
| Enalapril Maleate | 11 | $46 | $4 |
2017: 35 drugs
| Eliquis | 93 | $60,605 | $652 |
| Brilinta | 54 | $32,785 | $607 |
| Ranexa | 42 | $24,280 | $578 |
| Xarelto | 29 | $13,075 | $451 |
| Effient | 17 | $9,027 | $531 |
| Entresto | 13 | $7,407 | $570 |
| Metoprolol | 117 | $3,353 | $29 |
| Atorvastatin | 162 | $3,106 | $19 |
| Potassium Chloride | 78 | $2,477 | $32 |
| Ezetimibe | 16 | $2,375 | $148 |
| Rosuvastatin | 23 | $2,052 | $89 |
| Digoxin | 41 | $1,706 | $42 |
| Omega-3 Acid Ethyl Esters | 12 | $1,667 | $139 |
| Isosorbide Mononitrate Er | 85 | $1,638 | $19 |
| Metoprolol | 280 | $1,568 | $6 |
| Warfarin | 107 | $1,521 | $14 |
| Nitroglycerin | 55 | $1,338 | $24 |
| Amlodipine Besylate | 175 | $1,292 | $7 |
| Diltiazem | 38 | $1,148 | $30 |
| Hydralazine | 86 | $1,109 | $13 |
| Bumetanide | 12 | $1,098 | $92 |
| Digox | 21 | $1,091 | $52 |
| Clopidogrel | 80 | $1,042 | $13 |
| Losartan | 102 | $907 | $9 |
| Valsartan | 15 | $639 | $43 |
| Carvedilol | 79 | $634 | $8 |
| Furosemide | 124 | $600 | $5 |
| Simvastatin | 57 | $515 | $9 |
| Losartan-Hydrochlorothiazide | 35 | $448 | $13 |
| Lisinopril | 52 | $419 | $8 |
| Amiodarone | 25 | $354 | $14 |
| Pravastatin | 11 | $250 | $23 |
| Atenolol | 31 | $243 | $8 |
| Benazepril | 19 | $132 | $7 |
| Hydrochlorothiazide | 19 | $83 | $4 |
2016: 36 drugs
| Eliquis | 71 | $31,981 | $450 |
| Brilinta | 67 | $28,276 | $422 |
| Ranexa | 52 | $26,785 | $515 |
| Crestor | 20 | $10,337 | $517 |
| Xarelto | 19 | $9,734 | $512 |
| Pradaxa | 19 | $8,683 | $457 |
| Zetia | 26 | $7,775 | $299 |
| Metoprolol | 156 | $4,456 | $29 |
| Atorvastatin | 174 | $3,021 | $17 |
| Valsartan | 20 | $2,407 | $120 |
| Isosorbide Mononitrate Er | 92 | $1,930 | $21 |
| Hydralazine | 123 | $1,633 | $13 |
| Metoprolol | 218 | $1,354 | $6 |
| Clopidogrel | 72 | $1,268 | $18 |
| Digox | 20 | $1,223 | $61 |
| Nitrostat | 37 | $1,152 | $31 |
| Warfarin | 90 | $1,079 | $12 |
| Amlodipine Besylate | 164 | $1,064 | $6 |
| Digoxin | 23 | $911 | $40 |
| Potassium Chloride | 37 | $879 | $24 |
| Losartan | 114 | $864 | $8 |
| Lisinopril | 96 | $744 | $8 |
| Benazepril-Hydrochlorothiazide | 11 | $657 | $60 |
| Diltiazem | 15 | $654 | $44 |
| Simvastatin | 63 | $518 | $8 |
| Furosemide | 110 | $500 | $5 |
| Nitroglycerin | 12 | $490 | $41 |
| Carvedilol | 49 | $439 | $9 |
| Pravastatin | 27 | $419 | $16 |
| Losartan-Hydrochlorothiazide | 31 | $379 | $12 |
| Amiodarone | 28 | $365 | $13 |
| Atenolol | 47 | $281 | $6 |
| Benazepril | 22 | $203 | $9 |
| Lisinopril-Hydrochlorothiazide | 11 | $79 | $7 |
| Hydrochlorothiazide | 17 | $66 | $4 |
| Metformin | 11 | $63 | $6 |
2015: 38 drugs
| Ranexa | 43 | $22,654 | $527 |
| Brilinta | 54 | $15,961 | $296 |
| Crestor | 31 | $14,639 | $472 |
| Effient | 28 | $10,659 | $381 |
| Pradaxa | 18 | $7,405 | $411 |
| Eliquis | 21 | $7,231 | $344 |
| Multaq | 12 | $5,738 | $478 |
| Metoprolol | 143 | $4,893 | $34 |
| Xarelto | 13 | $4,825 | $371 |
| Zetia | 14 | $4,052 | $289 |
| Omega-3 Acid Ethyl Esters | 11 | $3,668 | $333 |
| Atorvastatin | 167 | $2,993 | $18 |
| Isosorbide Mononitrate Er | 135 | $2,618 | $19 |
| Livalo | 13 | $2,394 | $184 |
| Valsartan | 16 | $1,976 | $124 |
| Hydralazine | 132 | $1,711 | $13 |
| Clopidogrel | 79 | $1,232 | $16 |
| Metoprolol | 193 | $1,164 | $6 |
| Digox | 23 | $1,090 | $47 |
| Amlodipine Besylate | 164 | $1,076 | $7 |
| Amiodarone | 47 | $858 | $18 |
| Warfarin | 58 | $844 | $15 |
| Losartan | 91 | $744 | $8 |
| Nitrostat | 29 | $617 | $21 |
| Cartia Xt | 12 | $615 | $51 |
| Fenofibrate | 13 | $583 | $45 |
| Lisinopril | 103 | $555 | $5 |
| Furosemide | 110 | $531 | $5 |
| Potassium Chloride | 22 | $448 | $20 |
| Simvastatin | 60 | $427 | $7 |
| Diltiazem | 22 | $412 | $19 |
| Pravastatin | 18 | $407 | $23 |
| Atenolol | 54 | $406 | $8 |
| Enalapril Maleate | 11 | $376 | $34 |
| Carvedilol | 36 | $336 | $9 |
| Losartan-Hydrochlorothiazide | 27 | $292 | $11 |
| Benazepril | 26 | $213 | $8 |
| Hydrochlorothiazide | 34 | $156 | $5 |
2014: 38 drugs
| Ranexa | 53 | $22,196 | $419 |
| Effient | 41 | $15,625 | $381 |
| Crestor | 48 | $14,448 | $301 |
| Pradaxa | 11 | $6,045 | $550 |
| Metoprolol | 139 | $4,937 | $36 |
| Diovan | 13 | $4,524 | $348 |
| Atorvastatin | 165 | $4,044 | $25 |
| Multaq | 14 | $3,858 | $276 |
| Lovaza | 19 | $3,716 | $196 |
| Clopidogrel | 134 | $3,182 | $24 |
| Fenofibrate | 12 | $2,227 | $186 |
| Colcrys | 13 | $2,119 | $163 |
| Digox | 24 | $1,890 | $79 |
| Isosorbide Mononitrate Er | 92 | $1,600 | $17 |
| Hydralazine | 103 | $1,384 | $13 |
| Nifedipine Er | 13 | $1,167 | $90 |
| Amlodipine Besylate | 154 | $1,098 | $7 |
| Fenofibrate | 19 | $992 | $52 |
| Carvedilol | 77 | $942 | $12 |
| Losartan | 74 | $850 | $11 |
| Valsartan-Hydrochlorothiazide | 12 | $835 | $70 |
| Potassium Chloride | 17 | $782 | $46 |
| Pravastatin | 18 | $759 | $42 |
| Metoprolol | 109 | $646 | $6 |
| Warfarin | 38 | $627 | $16 |
| Simvastatin | 58 | $609 | $11 |
| Nitrostat | 38 | $551 | $14 |
| Lisinopril | 76 | $518 | $7 |
| Furosemide | 95 | $469 | $5 |
| Losartan-Hydrochlorothiazide | 18 | $421 | $23 |
| Atenolol | 51 | $401 | $8 |
| Amiodarone | 32 | $369 | $12 |
| Bumetanide | 18 | $293 | $16 |
| Diltiazem | 22 | $259 | $12 |
| Sotalol | 11 | $166 | $15 |
| Spironolactone | 15 | $121 | $8 |
| Benazepril | 12 | $114 | $10 |
| Hydrochlorothiazide | 15 | $110 | $7 |
2013: 36 drugs
| Ranexa | 69 | $20,248 | $293 |
| Crestor | 55 | $15,671 | $285 |
| Effient | 47 | $12,612 | $268 |
| Pradaxa | 22 | $9,747 | $443 |
| Diovan | 38 | $8,962 | $236 |
| Clopidogrel | 148 | $8,811 | $60 |
| Atorvastatin | 183 | $5,617 | $31 |
| Metoprolol | 125 | $4,728 | $38 |
| Lovaza | 22 | $4,337 | $197 |
| Brilinta | 14 | $3,454 | $247 |
| Fenofibrate | 22 | $2,579 | $117 |
| Isosorbide Mononitrate Er | 89 | $2,136 | $24 |
| Valsartan-Hydrochlorothiazide | 18 | $1,789 | $99 |
| Colcrys | 11 | $1,699 | $154 |
| Fenofibrate | 37 | $1,265 | $34 |
| Cartia Xt | 19 | $1,229 | $65 |
| Losartan | 76 | $1,206 | $16 |
| Metoprolol | 132 | $1,095 | $8 |
| Simvastatin | 77 | $968 | $13 |
| Amlodipine Besylate | 103 | $906 | $9 |
| Carvedilol | 57 | $759 | $13 |
| Hydralazine | 44 | $754 | $17 |
| Lisinopril | 89 | $717 | $8 |
| Warfarin | 37 | $650 | $18 |
| Potassium Chloride | 27 | $569 | $21 |
| Losartan-Hydrochlorothiazide | 32 | $557 | $17 |
| Pravastatin | 35 | $531 | $15 |
| Furosemide | 88 | $459 | $5 |
| Klor-Con 10 | 11 | $457 | $42 |
| Digox | 18 | $410 | $23 |
| Atenolol | 50 | $388 | $8 |
| Amiodarone | 30 | $370 | $12 |
| Nitrostat | 23 | $269 | $12 |
| Benazepril | 22 | $231 | $10 |
| Spironolactone | 11 | $142 | $13 |
| Hydrochlorothiazide | 24 | $134 | $6 |
Money from drug and device companies
$414 in 2025
| 2025 | 11 | 21 | None | $414 |
| 2024 | 9 | 19 | None | $401 |
| 2023 | 9 | 32 | None | $594 |
| 2022 | 7 | 12 | None | $242 |
| 2021 | 9 | 18 | None | $359 |
| 2020 | 4 | 5 | None | $142 |
| 2019 | 7 | 41 | None | $378 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Eliquis | $151 | 9 payments
|
| Amgen | Repatha | $37 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $33 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $32 | 2 payments
|
| Novartis Pharmaceuticals | Leqvio | $32 | 1 payment
|
| Heartflow | Ffrct | $27 | 1 payment
|
See all 21 published payments
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-18 | Kerendia | $33 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-09 | Eliquis | $10 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-26 | Eliquis | $14 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-11-20 | Lifevest | $12 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-06 | Eliquis | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-06 | Eliquis | $5 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-10-23 | Lifevest | $20 |
| Heartflow | Meals · 2025-10-16 | Ffrct | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-06 | Eliquis | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-04 | Eliquis | $15 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-07 | Eliquis | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-07 | Eliquis | $4 |
| Amgen | Meals · 2025-07-24 | Repatha | $20 |
| Baxter Healthcare | Meals · 2025-06-12 | Hillrom - Carnation Ambulatory Monitor | $15 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-05 | Eliquis | $34 |
| Novo Nordisk | Meals · 2025-05-29 | Wegovy | $21 |
| Boston Scientific | Meals · 2025-05-01 | Watchman Flx | $18 |
| Pfizer | Meals · 2025-04-16 | Eliquis | $25 |
| Amgen | Meals · 2025-04-03 | Repatha | $17 |
| Novartis Pharmaceuticals | Meals · 2025-03-06 | Leqvio | $32 |
| Edwards Lifesciences | Meals · 2025-02-27 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $401
| Novartis Pharmaceuticals | Entresto | $139 | 7 payments
|
| Boston Scientific | Watchman Flx | $61 | 3 payments
|
| Pfizer | Eliquis | $47 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $38 | 2 payments
|
| Amgen | Repatha | $27 | 1 payment
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $26 | 1 payment
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $26 | 1 payment
|
| Novo Nordisk | Ozempic | $19 | 1 payment
|
| Abbott Laboratories | Amplatzer Amulet | $18 | 1 payment
|
2023: $594
| Pfizer | Eliquis | $137 | 12 payments
|
| Merck Sharp & Dohme | Verquvo | $121 | 5 payments
|
| Novartis Pharmaceuticals | Entresto | $113 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $78 | 4 payments
|
| Boston Scientific | Watchman Flx | $42 | 2 payments
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $35 | 1 payment
|
| Amgen | Repatha | $25 | 1 payment
|
| Abbott Laboratories | Mitraclip | $21 | 1 payment
|
| Novo Nordisk | Rybelsus | $21 | 1 payment
|
2022: $242
| Merck Sharp & Dohme | Verquvo | $63 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $52 | 3 payments
|
| Boston Scientific | Watchman Access System | $41 | 1 payment
|
| Novo Nordisk | Rybelsus | $31 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $23 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $18 | 1 payment
|
| Pfizer | Eliquis | $14 | 1 payment
|
2021: $359
| AstraZeneca Pharmaceuticals LP | Brilinta | $145 | 4 payments
|
| Novartis Pharmaceuticals | Entresto | $53 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Verquvo | $50 | 3 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $25 | 1 payment
|
| Amgen | Repatha | $21 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $19 | 1 payment
|
| Pfizer | Eliquis | $16 | 1 payment
|
| Novo Nordisk | Rybelsus | $15 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $14 | 1 payment
|
2020: $142
| Bardy Diagnostics | Carnation Ambulatory Monitor | $82 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $22 | 1 payment
|
| Abbott Laboratories | Mitra Clip System | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $18 | 1 payment
|
2019: $378
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $219 | 31 payments
|
| Novartis Pharmaceuticals | Entresto | $51 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $36 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $28 | 2 payments
|
| Abbott Laboratories | Confirm Rx | $21 | 1 payment
|
| Portola Pharmaceuticals | Andexxa | $12 | 1 payment
|
| Pfizer | Eliquis | $11 | 1 payment
|
Checkups this office reported
2 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Patients can see their records onlinePatients who were given electronic access to their health information | 93%That's most of the people this applied to. | 356 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 96%That's most of the people this applied to. | 473 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Implementation of improvements that contribute to more timely communication of test results
- Implementation of medication management practice improvements
- Reports cases to public health electronically
- Exempt from immunization registry reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
Professional record
- NPI
- 1386675981
- Licence
- CA A76357California A76357: Current · expires 2027-08-31
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 2081 Forest Ave, Suite 4, San Jose, CA, 95128
- NPI first listed
- 2006-07-05
- NPI last updated
- 2013-02-28
This is when the NPI record was last certified, not a medical board exam.